# Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

> **NCT02808208** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 74 (estimated)

## Conditions studied

- End Stage Renal Disease (ESRD)
- Vascular Access Complication

## Interventions

- **BIOLOGICAL:** Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)
- **DRUG:** Placebo
- **BIOLOGICAL:** Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)

## Key facts

- **NCT ID:** NCT02808208
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-07
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808208, "Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02808208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*